AKAP4 and non-small cell lung carcinoma: Thus, our findings suggest the potential utility of measuring anti-SP17/AKAP4/PTTG1 antibodies in patients' sera as a marker of immunogenicity against these antigens and, possibly, as a diagnostic tool in NSCLC patients.